RxDoctor Payments Data

Aarati Malliah, MD

Gastroenterology · Philadelphia, PANPI 1962613125

Payments from drug & device makers

$5,945in general payments, 2019–2025

Across 405 payments — averaging $14.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$975
  • Takeda Pharmaceuticals U.S.A., Inc.$571
  • Bristol Myers Squibb$462
  • Johnson & Johnson$409
  • Lilly USA, LLC$162
  • plus $2K from 25 others

What the payments were for

  • Food & beverage$5,918100%
  • Education$270%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,945 in reported general payments places this provider in the 65th percentile of 935 gastroenterology providers in Pennsylvania.

See all gastroenterology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$199,421
Medicare patients
517
Services billed
4,606

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi On-BodyRisankizumab-Rzaa13$266,052
RinvoqUpadacitinib14$166,401
Humira PenAdalimumab12$81,739
LinzessLinaclotide51$66,553
Alosetron Hcl22$32,336
ZenpepLipase/Protease/Amylase13$26,877
XifaxanRifaximin12$26,685
MotegrityPrucalopride Succinate12$13,692
Dexlansoprazole DrDexlansoprazole14$7,378
CholestyramineCholestyramine (With Sugar)34$5,519
Omeprazole275$3,931
Esomeprazole Magnesium46$3,877
Pantoprazole Sodium110$3,469
Lubiprostone11$2,462
Colestipol Hcl37$2,387

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq, Linzess$1,668$232,95465 claims
Aimmune Therapeutics, Inc.Zenpep$94$26,87713 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$975$26,68512 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$571$13,69212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 935 gastroenterology providers in Pennsylvania.

Other gastroenterology in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →